Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

61. Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency

Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency Final Appraisal Recommendation Advice No: 2215 – July 2015 Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution Limited submission by Kora Healthcare Additional note(s): • Magnaspartate ® is the first licensed oral magnesium product available in Wales for the treatment and prevention of magnesium deficiency. In reaching the above recommendation AWMSG has taken (...) every three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2215: Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution. July 2015. Recommendation of AWMSG Magnesium aspartate dihydrate (Magnaspartate ® ) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency

2015 All Wales Medicines Strategy Group

62. Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block?

Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? BestBets: Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Report By: Dr Peter Kilgour, Dr Babajide Oni - Emergency Medicine ST2 Search checked by Dr Dianne Tabone , Dr Hisham Ghanayem (ST5) - Consultant in Emergency Medicine Preston and (ST5 Central Manchester (...) ) Institution: Royal Preston Hospital, Preston, Lancs, UK Date Submitted: 11th November 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with a femoral neck fracture] does [magnesium prolong the analgaesic effect of bupivacaine] in [a fascia iliaca nerve block]? Clinical Scenario An 89-year-old woman presents to your emergency department following a fall. She is complaining of severe pain in her right hip area. A plain radiograph shows

2015 BestBETS

63. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. (PubMed)

Prehospital use of magnesium sulfate as neuroprotection in acute stroke. Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents.We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning (...) within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age

Full Text available with Trip Pro

2015 NEJM

64. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. (PubMed)

Prehospital use of magnesium sulfate as neuroprotection in acute stroke. Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents.We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning (...) within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age

Full Text available with Trip Pro

2015 NEJM

65. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations?

Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? Systematic Review Snapshot TAKE-HOME MESSAGE Administration of intravenous magnesium sulfate may result in a modest reduction in hospital admissions among adult ED patients with acute asthma who have not responded to standard therapies. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? EBEM Commentators (...) intravenous magnesium sulfate during 15 to 30 minutes experienced a small but signi?cant reduction in rates of hospital admission (odds ratio [OR] 0.75), with minimal heterogeneity observed (I 2 ¼28%). When the 3 studies at high or unclear risk of bias for blinding were removed, the pooled effect for hospital admission was similar (OR 0.72; 95% con?dence interval [CI] 0.57 to 0.91). There was no signi?cant change in spirometric parameters (eg, peak expiratory ?ow) as well. All studies included

2015 Annals of Emergency Medicine Systematic Review Snapshots

66. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation (PubMed)

Intrapartum magnesium sulfate and need for intensive delivery room resuscitation To evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection (MgSO4-FN) with the delivery room resuscitation and neonatal outcomes of preterm infants in an era of minimisation of invasive mechanical ventilation.Retrospective cohort study.Neonatal intensive care units in the Canadian Neonatal Network.Preterm infants (23(0) to 31(6) weeks gestational age) born in 2011 or 2012. Resuscitation

Full Text available with Trip Pro

2014 EvidenceUpdates

67. Magnesium sulphate for preventing preterm birth in threatened preterm labour. (PubMed)

Magnesium sulphate for preventing preterm birth in threatened preterm labour. Magnesium sulphate has been used in some settings as a tocolytic agent to inhibit uterine activity in women in preterm labour with the aim of preventing preterm birth.To assess the effects of magnesium sulphate therapy given to women in threatened preterm labour with the aim of preventing preterm birth and its sequelae.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (last searched 31 January (...) 2014).Randomised controlled trials of magnesium sulphate as the only tocolytic, administered by any route, compared with either placebo, no treatment or alternative tocolytic therapy (not magnesium sulphate) to women considered to be in preterm labour.At least two review authors assessed trial eligibility and risk of bias and undertook data extraction independently.The 37 included trials (total of 3571 women and over 3600 babies) were generally of moderate to high risk of bias. Antenatal magnesium

Full Text available with Trip Pro

2014 Cochrane

68. Adults with acute asthma: can intravenous magnesium sulfate help?

Adults with acute asthma: can intravenous magnesium sulfate help? Adults with acute asthma: can intravenous magnesium sulfate help? - Evidently Cochrane Search and hit Go By May 30, 2014 // How useful is intravenous magnesium sulfate in treating people arriving in the Emergency Department with asthma attacks? Can it help some to avoid hospital admission? In this guest post, Dr Chris Cates looks at the latest evidence. The full report of the large “3Mg trial” of intravenous or nebulised (...) magnesium sulfate in adults with asthma exacerbations was published in April 2014[ ]. The authors concluded that they “were unable to demonstrate any clinically worthwhile benefit from magnesium sulphate in acute severe asthma”, and thereby questioned whether there was a place for using intravenous magnesium sulfate in adults with an asthma exacerbation who had not responded to the first line treatments of steroid tablets (on injections) in combination with nebulised salbutamol and ipratropium. However

2014 Evidently Cochrane

69. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma

The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma The 3Mg Trial: A randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2014 NIHR HTA programme

70. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. (PubMed)

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into school age have not been reported from randomized trials.To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral outcomes at school age.The (...) ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation. Children who survived from the 14 centers who participated in the school-age follow-up (n = 443 magnesium; n = 424 placebo) were invited for an assessment at 6 to 11 years of age between 2005 and 2011.Mortality, cerebral palsy, motor

Full Text available with Trip Pro

2014 JAMA

71. Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores

Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The addition of nebulised magnesium

2014 Evidence-Based Medicine (Requires free registration)

72. Effect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulations (PubMed)

Effect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulations Nocturnal leg cramps (NLC) are common in primary care and may cause severe pain and sleep disturbance. We systematically reviewed the effectiveness of magnesium in treating NLC and the side-effect profile of magnesium compared to placebo.We searched Medline, Embase, Cochrane Library, ClinicalTrials.gov, the International Standard Randomised Controlled (...) Trial Number and the International Clinical Trials Registry Platform registries until August 2012. All randomized controlled trials (RCTs) comparing magnesium therapy for NLC in adults with any other comparator were eligible. Two investigators independently selected, extracted data from and rated the risk of bias of relevant studies. To compensate for the heterogeneity in outcome measures, simulations were used to summarize the data.Seven RCTs were included in the review (n = 361), all comparing

Full Text available with Trip Pro

2013 EvidenceUpdates

73. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children

MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page

2013 NIHR HTA programme

74. Magnesium for alcohol withdrawal. (PubMed)

Magnesium for alcohol withdrawal. Patients have been given magnesium to treat or prevent alcohol withdrawal syndrome (AWS). Evidence to support this practice is limited, and is often based on the controversial link between hypomagnesaemia and AWS.To assess the effects of magnesium for the prevention or treatment of AWS in hospitalised adults.We searched the Cochrane Drugs and Alcohol Group Register of Controlled Trials (August 2012), PubMed (from 1966 to August 2012 ), EMBASE (from 1988 (...) to August 2012), CINAHL (from 1982 to March 2010), Web of Science (1965 to August 2012). We also carried out Internet searches.Randomised or quasi-randomised trials of magnesium for hospitalised adults with, or at risk for, acute alcohol withdrawal.Two review authors independently extracted data with a standardised data extraction form, contacting the correspondence investigator if the necessary information was not available in the reports. Dichotomous outcomes were analysed by calculating the risk

2013 Cochrane

75. Magnesium sulphate for women at term for neuroprotection of the fetus. (PubMed)

Magnesium sulphate for women at term for neuroprotection of the fetus. Magnesium sulphate is extensively used in obstetrics for the treatment and prevention of eclampsia. A recent meta-analysis has shown that magnesium sulphate is an effective fetal neuroprotective agent when given antenatally to women at risk of very preterm birth. Term infants account for more than half of all cases of cerebral palsy, and the incidence has remained fairly constant. It is important to assess if antenatal (...) administration of magnesium sulphate to women at term protects the fetus from brain injury, and associated neurosensory disabilities including cerebral palsy.To assess the effectiveness of magnesium sulphate given to women at term as a neuroprotective agent for the fetus.We searched the Cochrane Pregnancy and Childbirth Group's Trial Register (31 July 2012) and the reference lists of other Cochrane reviews assessing magnesium sulphate in pregnancy.Randomised controlled trials comparing antenatally

Full Text available with Trip Pro

2013 Cochrane

76. Prophylactic Magnesium Does Not Prevent Atrial Fibrillation After Cardiac Surgery: A Meta-Analysis (PubMed)

Prophylactic Magnesium Does Not Prevent Atrial Fibrillation After Cardiac Surgery: A Meta-Analysis Atrial fibrillation (AF) is a common complication after cardiac surgery. Previous meta-analyses have concluded prophylactic magnesium (Mg) prevents postoperative AF, although with a significant degree of heterogeneity among included studies. Recently, the largest randomized, controlled trial published to date (but not included in prior published meta-analyses) concluded that Mg sulfate

2013 EvidenceUpdates

77. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials

Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

78. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Pre Prev venting recurrent h enting recurrent hypomagnesaemia: or ypomagnesaemia: oral al magnesium gly magnesium glycerophosphate cerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate

2013 National Institute for Health and Clinical Excellence - Advice

79. Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia

Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Article Text

2013 Evidence-Based Mental Health

80. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies

Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.